144 related articles for article (PubMed ID: 29750753)
1. Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center.
Afzal MZ; Shirai K
Melanoma Res; 2018 Aug; 28(4):341-347. PubMed ID: 29750753
[TBL] [Abstract][Full Text] [Related]
2. Combination of denosumab and immune checkpoint inhibition: experience in 29 patients with metastatic melanoma and bone metastases.
Angela Y; Haferkamp S; Weishaupt C; Ugurel S; Becker JC; Oberndörfer F; Alar V; Satzger I; Gutzmer R
Cancer Immunol Immunother; 2019 Jul; 68(7):1187-1194. PubMed ID: 31187176
[TBL] [Abstract][Full Text] [Related]
3. Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials.
Yun S; Vincelette ND; Green MR; Wahner Hendrickson AE; Abraham I
Cancer Med; 2016 Jul; 5(7):1481-91. PubMed ID: 27167347
[TBL] [Abstract][Full Text] [Related]
4. The Effectiveness of Adjuvant PD-1 Inhibitors in Patients With Surgically Resected Stage III/IV Acral Melanoma.
Arak H; Erkiliç S; Yaslikaya Ş; Eylemer Mocan E; Aktaş G; Özdemir M; Semiz HS; Kiliçkap S; Özalp FR; Sever ÖN; Akdağ G; Ağaoğlu AB; Özçelik M; Sari M; Arcagök M; Anik H; Yayla ŞB; Sever N; Açar FP; Bayrakçi İ; Turhal S; Ayhan M; Kuş T;
J Immunother; 2024 Jun; 47(5):182-189. PubMed ID: 38333962
[TBL] [Abstract][Full Text] [Related]
5. Severe autoimmune hemolytic anemia following immunotherapy with checkpoint inhibitors in two patients with metastatic melanoma: a case report.
Fetter T; Fietz S; Bertlich M; Braegelmann C; de Vos-Hillebrand L; Wenzel J; Heine A; Landsberg J; Jansen P
Front Immunol; 2024; 15():1342845. PubMed ID: 38571955
[TBL] [Abstract][Full Text] [Related]
6. Checkpoint inhibitors: Better outcomes among advanced cutaneous head and neck melanoma patients.
Hirshoren N; Yoeli R; Cohen JE; Weinberger JM; Kaplan N; Merims S; Peretz T; Lotem M
PLoS One; 2020; 15(4):e0231038. PubMed ID: 32282861
[TBL] [Abstract][Full Text] [Related]
7. Indicators of responsiveness to immune checkpoint inhibitors.
Shields BD; Mahmoud F; Taylor EM; Byrum SD; Sengupta D; Koss B; Baldini G; Ransom S; Cline K; Mackintosh SG; Edmondson RD; Shalin S; Tackett AJ
Sci Rep; 2017 Apr; 7(1):807. PubMed ID: 28400597
[TBL] [Abstract][Full Text] [Related]
8. Determinants of overall survival in patients with metastatic uveal melanoma.
Demkowicz P; Pointdujour-Lim R; Miguez S; Lee Y; Jones BSCL; Barker CA; Bosenberg M; Abramson DH; Shoushtari AN; Kluger H; Francis JH; Sznol M; Bakhoum MF
Cancer; 2023 Oct; 129(20):3275-3286. PubMed ID: 37382208
[TBL] [Abstract][Full Text] [Related]
9. Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients.
Vera Aguilera J; Paludo J; McWilliams RR; Zhang H; Li Y; Kumar AB; Failing J; Kottschade LA; Block MS; Markovic SN; Dong H; Dronca RS; Yan Y
Melanoma Res; 2020 Aug; 30(4):364-375. PubMed ID: 32404734
[TBL] [Abstract][Full Text] [Related]
10. The RANKL inhibitor denosumab in combination with dual checkpoint inhibition is associated with increased CXCL-13 serum concentrations.
Schaper-Gerhardt K; Gutzmer R; Angela Y; Zimmer L; Livingstone E; Schadendorf D; Hassel JC; Weishaupt C; Remes B; Kubat L; Spassova I; Becker JC
Eur J Cancer; 2024 May; 202():113984. PubMed ID: 38479119
[TBL] [Abstract][Full Text] [Related]
11. TIGIT
Tsakmaklis A; Farowski F; Zenner R; Lesker TR; Strowig T; Schlößer H; Lehmann J; von Bergwelt-Baildon M; Mauch C; Schlaak M; Knuever J; Schweinsberg V; Heinzerling LM; Vehreschild MJGT
BMC Cancer; 2023 Nov; 23(1):1160. PubMed ID: 38017389
[TBL] [Abstract][Full Text] [Related]
12. Frequency and characteristics of immune-related thyroid adverse events in patients with resected stage III/IV melanoma treated with adjuvant PD-1 inhibitors: a national cohort study.
Christensen SK; Winther ML; Laursen IJ; Madsen FS; Brink C; Brix TH; Ellebaek E; Svane IM; Hansen FS; Haslund C; Laursen OK; Schmidt H; Larsen ID; Bastholt L; Ruhlmann CH
Support Care Cancer; 2024 Apr; 32(5):281. PubMed ID: 38598052
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the efficacy of combination and single-agent immunotherapies in real-world patterns of disease progression and survival of metastatic melanoma patients.
Ko B; Tao K; Brennan L; Rakhade S; Chan CX; Moone JY; Zhu R; Sher A; Wang S; Bracero Y; Fullerton B; McLellan B; Geskin LJ; Saenger YM
Melanoma Res; 2024 Apr; 34(2):134-141. PubMed ID: 38181115
[TBL] [Abstract][Full Text] [Related]
14. Anti-melanoma Effects of Resiquimod (RSQ) In Vitro and in Combination with Immune Checkpoint Blockade In Vivo.
Tambunlertchai S; Geary SM; Naguib YW; Salem AK
AAPS J; 2023 Jun; 25(4):57. PubMed ID: 37266761
[TBL] [Abstract][Full Text] [Related]
15. Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases.
Pires da Silva I; Li I; Ugurel S; Serra-Bellver P; Andhale A; Burnette H; Aya F; Conway JW; Braden J; Carlino MS; Menzies AM; Weichenthal M; Mohr P; Gutzmer R; Arance AM; Johnson DB; Lorigan P; Schadendorf D; Lo SN; Long GV
Eur J Cancer; 2024 May; 205():114101. PubMed ID: 38735161
[TBL] [Abstract][Full Text] [Related]
16. The Future of Checkpoint Inhibitors in Uveal Melanoma: A Narrative Review.
Wang J; Li Z; Yin H
Ophthalmol Ther; 2024 May; 13(5):1103-1123. PubMed ID: 38498280
[TBL] [Abstract][Full Text] [Related]
17. The real-world data of immune-checkpoint inhibitor combination therapy for unresectable or metastatic esophageal cancer: a multi-institutional cohort study.
Sato S; Ssuzuki T; Chinen T; Yamaguchi H; Suzuki Y; Hokamura N; Saze Z; Kono K; Takahashi K; Yano F; Kunisaki C; Kosaka T; Endo I; Ichikawa Y; Miyawaki Y; Sato H; Shimada H
Int J Clin Oncol; 2024 Apr; ():. PubMed ID: 38679627
[TBL] [Abstract][Full Text] [Related]
18. Emerging immune therapy of metastatic melanoma in the older patient: does age really matter?
Hegde UP; Mukherji B; Grant-Kels JM
Melanoma Manag; 2016 Mar; 3(1):9-12. PubMed ID: 30190868
[No Abstract] [Full Text] [Related]
19. The neurotoxic effects of immune checkpoint inhibitor therapy for melanoma.
Spain L; Wong R
Melanoma Manag; 2019 May; 6(2):MMT16. PubMed ID: 31406561
[No Abstract] [Full Text] [Related]
20. Eosinophilic granulocytes as a potential prognostic marker for cancer progression and therapeutic response in malignant melanoma.
Brand CL; Hunger RE; Seyed Jafari SM
Front Oncol; 2024; 14():1366081. PubMed ID: 38756652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
